Wednesday, January 4, 2012

Stock Alert - Achillion's (ACHN) hepatitis C drug, which is in a mid-stage trial - 1/4/12

The FDA grants fast-track status to Achillion's (ACHN) hepatitis C drug, which is in a mid-stage trial. Shares +3.3% premarket

For the latest updates on the stock market, visit, 
http://daytradingstock-blog.blogspot.com/